GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Minerva Surgical Inc (OTCPK:UTRS) » Definitions » Cash Ratio

Minerva Surgical (Minerva Surgical) Cash Ratio : 0.52 (As of Sep. 2023)


View and export this data going back to 2021. Start your Free Trial

What is Minerva Surgical Cash Ratio?

The Cash Ratio measures a company’s ability to meet its short-term obligations with cash and near-cash resources. It is calculated as a company's Cash, Cash Equivalents, Marketable Securities divides by its Total Current Liabilities. Minerva Surgical's Cash Ratio for the quarter that ended in Sep. 2023 was 0.52.

Minerva Surgical has a Cash Ratio of 0.52. It indicates that there are more current liabilities than Cash, Cash Equivalents, Marketable Securities, and the company does not have sufficient cash on hand to pay off its short-term debt.

The historical rank and industry rank for Minerva Surgical's Cash Ratio or its related term are showing as below:

UTRS' s Cash Ratio Range Over the Past 10 Years
Min: 0.09   Med: 0.77   Max: 1.78
Current: 0.52

During the past 4 years, Minerva Surgical's highest Cash Ratio was 1.78. The lowest was 0.09. And the median was 0.77.

UTRS's Cash Ratio is ranked worse than
68.65% of 855 companies
in the Medical Devices & Instruments industry
Industry Median: 1.23 vs UTRS: 0.52

Minerva Surgical Cash Ratio Historical Data

The historical data trend for Minerva Surgical's Cash Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Minerva Surgical Cash Ratio Chart

Minerva Surgical Annual Data
Trend Dec19 Dec20 Dec21 Dec22
Cash Ratio
1.78 0.52 1.78 0.49

Minerva Surgical Quarterly Data
Dec19 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23
Cash Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.66 0.49 1.50 0.87 0.52

Competitive Comparison of Minerva Surgical's Cash Ratio

For the Medical Devices subindustry, Minerva Surgical's Cash Ratio, along with its competitors' market caps and Cash Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Minerva Surgical's Cash Ratio Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Minerva Surgical's Cash Ratio distribution charts can be found below:

* The bar in red indicates where Minerva Surgical's Cash Ratio falls into.



Minerva Surgical Cash Ratio Calculation

The Cash Ratio measures a company's ability to meet its short-term obligations with its cash and near-cash resources.

Minerva Surgical's Cash Ratio for the fiscal year that ended in Dec. 2022 is calculated as:

Cash Ratio (A: Dec. 2022 )=Cash, Cash Equivalents, Marketable Securities/Total Current Liabilities
=6.942/14.278
=0.49

Minerva Surgical's Cash Ratio for the quarter that ended in Sep. 2023 is calculated as:

Cash Ratio (Q: Sep. 2023 )=Cash, Cash Equivalents, Marketable Securities/Total Current Liabilities
=11.125/21.251
=0.52

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Minerva Surgical  (OTCPK:UTRS) Cash Ratio Explanation

The cash ratio is more conservative than other liquidity ratios, such as Quick Ratio and Current Ratio, because it only considers a company's most liquid resources. The numerator of cash ratio only considers Cash, Cash Equivalents and marketable securities. Other current assets, such as accounts receivable and inventories, are not included. The rationale is that these assets may require time to be transformed into cash, and the amount of money received is also uncertain.

The cash ratio shows a company’s ability to pay all current liabilities immediately without selling or liquidating other assets. Generally speaking, a higher cash ratio suggests the company has a stronger ability to cover its short-term debt. However, a high cash ratio could also indicate inefficient management: the company is inefficient in making full utilization of cash to invest protential profitable project. It may also suggest that the company is not confident about future profitability.

In general, the higher the cash ratio, the better the company's liquidity position.


Minerva Surgical Cash Ratio Related Terms

Thank you for viewing the detailed overview of Minerva Surgical's Cash Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Minerva Surgical (Minerva Surgical) Business Description

Traded in Other Exchanges
N/A
Address
4255 Burton Drive, Santa Clara, CA, USA, 95054
Minerva Surgical Inc is a medical device company that develops therapeutic devices that treat abnormal uterine bleeding in a minimally invasive manner. The Company operates and manages its business as one reportable and operating segment, which is the business of research, development, and sale of therapeutic devices for abnormal uterine bleeding treatment.
Executives
Daniel Cohen director C/O ACCELMED, 848 BRICKELL AVE, #901, MIAMI FL 33131
Accelmed Partners Ii L.p. 10 percent owner 2875 NE 191ST, SUITE 500, AVENTURA FL 33180
New Enterprise Associates 13 Lp 10 percent owner 1119 ST PAUL STREET, BALTIMORE MD 21202
Uri Geiger director, 10 percent owner 221 LATHROP WAY, SUITE I, SACRAMENTO CA 95815
Todd Usen director, officer: Chief Executive Officer C/O MINERVA SURGICAL, INC., 4255 BURTON DRIVE, SANTA CLARA CA 95054
Derrick Sung director C/O IRHYTHM TECHNOLOGIES, INC., 650 TOWNSEND STREET, SUITE 380, SAN FRANCISCO CA 94103
David M Clapper director, officer: President and CEO 3003 TASMAN DRIVE, SANTA CLARA CA 95054
Novo Holdings A/s 10 percent owner TUBORG HAVNEVEJ 19, HELLERUP G7 2900
Jaffe Ross A Md director ONE SANSOME STREET, SUITE 3630, SAN FRANCISCO CA 94104
Evgueni V. Skalnyi officer: VP Medical Affairs C/O MINERVA SURGICAL, INC., 4225 BURTON DRIVE, SANTA CLARA CA 95054
Dominique J. Filloux officer: COO C/O MINERVA SURGICAL, INC., 4225 BURTON DRIVE, SANTA CLARA CA 95054
Joel R Jung officer: CFO 1401 HARBOR BAY PARKWAY, ALAMEDA CA 94502
Niquette L. Hunt director SOLITON, INC., 5304 ASHBROOK DRIVE, HOUSTON TX 77081
Jill Anderson director 1600 WEST MERIT PARKWAY, SOUTH JORDAN UT 84095
Nea Partners 13, Limited Partnership 10 percent owner 1119 ST. PAUL STREET, BALTIMORE MD 21202

Minerva Surgical (Minerva Surgical) Headlines

From GuruFocus

Minerva Surgical to Present at Upcoming Investor Conferences

By GuruFocusNews GuruFocusNews 05-30-2022

Minerva Surgical Announces AUB Awareness Day

By GuruFocusNews GuruFocusNews 04-26-2022

Minerva Surgical to Present at Upcoming Investor Conferences

By GuruFocusNews GuruFocusNews 06-29-2022

Minerva Surgical to Present at the 41st Annual J.P. Morgan Healthcare Conference

By Stock market mentor Stock market mentor 01-03-2023

Minerva Surgical to Present at Upcoming Investor Conferences

By GuruFocusNews GuruFocusNews 06-19-2022

Minerva Surgical to Announce First Quarter 2023 Financial Results

By sperokesalga sperokesalga 04-18-2023

Minerva Surgical Announces Time To Talk Campaign

By PurpleRose PurpleRose 08-03-2022

Minerva Surgical to Present at Upcoming Investor Conferences

By GuruFocusNews GuruFocusNews 05-20-2022

Minerva Surgical Closes $30 Million Private Placement of Common Stock

By sperokesalga sperokesalga 02-09-2023